Kai-Keen Shiu shared a post on X by Smitha Krishnamurthi adding:

“NICHE2, NICHE3 and IMHOTEP beautifully summarised by Smitha Krishnamurthi

Q1: Is ctDNA prediction of pCR only relevant for NOM?
Q2: If ctDNA -ve then no adjuvant therapy needed? (I predict)
Less is more IMO + still need biomarkers CURE!”

Quoting Smitha Krishnamurthi’s post below:

“NICHE2: 3yDFS 100 % drop + rapid ctDNA clearance NICHE 3 relatlimab+nivo: 68% pCR similar to NICHE2 but numerically increased gr 3-4AE
IMHOTEP: pCR 53% with 1-2 doses pembro

Myriam Chalabi, Peter de Gooyer, Christelle de la Fouchardiere

Superb discussion by Jen Seligmann.”

Source: Kai-Keen Shiu/X and Smitha Krishnamurthi/X

Kai-Keen Shiu is a Medical Oncology Consultant at University College London Hospitals and Honorary Associate Professor at the UCL Cancer Institute. He specializes in oesophageal, stomach, colorectal, and hepatobiliary cancers, as well as cancers of unknown primary (CUP). Dr. Shiu leads the Cancer of Unknown Primary and Acute Oncology Services at UCLH. His research focuses on immunotherapy for gastrointestinal cancers and CUP.

Smitha Krishnamurthi is a Staff Physician at Cleveland Clinic in the Department of Hematology and Medical Oncology and an Associate Professor in the Department of Medicine, Division of Hematology and Oncology, at the School of Medicine. She is also a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center.

Kai-Keen Shiu: NICHE2, NICHE3 and IMHOTEP summarised by Smitha Krishnamurthi